Summary

There is a need for new antibiotics to treat the rising incidence of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections caused by Gram-positive bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, including the multidrug resistant and methicillin-resistant (MRSA) forms of these bacteria. This article presents a poster [Jandourek et al. ICAAC 2012 L1–300c] with results from the Clinical Assessment Program and Teflaro® Utilization Registry cohort [CAPTURE] study that showed ceftaroline produced good clinical outcomes when used as monotherapy to treat CABP due to MRSA.